PL3373914T3 - Trwała przy przechowywaniu kompozycja zawierająca rifaksyminę alfa - Google Patents
Trwała przy przechowywaniu kompozycja zawierająca rifaksyminę alfaInfo
- Publication number
- PL3373914T3 PL3373914T3 PL17712504T PL17712504T PL3373914T3 PL 3373914 T3 PL3373914 T3 PL 3373914T3 PL 17712504 T PL17712504 T PL 17712504T PL 17712504 T PL17712504 T PL 17712504T PL 3373914 T3 PL3373914 T3 PL 3373914T3
- Authority
- PL
- Poland
- Prior art keywords
- storage stable
- stable composition
- rifaximin alpha
- rifaximin
- alpha
- Prior art date
Links
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title 1
- 229960003040 rifaximin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162417 | 2016-03-24 | ||
| EP17712504.4A EP3373914B2 (en) | 2016-03-24 | 2017-03-22 | Storage stable composition comprising rifaximin alpha |
| PCT/EP2017/056798 WO2017162726A1 (en) | 2016-03-24 | 2017-03-22 | Storage stable composition comprising rifaximin alpha |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL3373914T3 true PL3373914T3 (pl) | 2019-10-31 |
| PL3373914T5 PL3373914T5 (pl) | 2022-10-17 |
Family
ID=55637249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17712504.4T PL3373914T5 (pl) | 2016-03-24 | 2017-03-22 | Trwała przy przechowywaniu kompozycja zawierająca rifaksyminę alfa |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10842782B2 (pl) |
| EP (2) | EP3536311B1 (pl) |
| AU (1) | AU2017237469B2 (pl) |
| CA (1) | CA3003108C (pl) |
| ES (1) | ES2738024T5 (pl) |
| HU (1) | HUE044432T2 (pl) |
| PL (1) | PL3373914T5 (pl) |
| TR (1) | TR201909029T4 (pl) |
| WO (1) | WO2017162726A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1698630T3 (pl) | 2005-03-03 | 2014-12-31 | Alfasigma Spa | Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych |
| US9938298B2 (en) | 2014-05-12 | 2018-04-10 | Alfa Wassermann S.P.A. | Solvated crystal form of rifaximin, production, compositions and uses thereof |
| ES2700423T3 (es) | 2016-03-24 | 2019-02-15 | Sandoz Ag | Composición farmacéutica que contiene rifaximina alfa y delta |
| CN113747654B (zh) * | 2020-05-27 | 2023-08-04 | 宏启胜精密电子(秦皇岛)有限公司 | 柔性电路板及其制作方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1883776U (de) * | 1963-07-31 | 1963-11-28 | Schering Ag | Tablettendurchdruckpackung. |
| US7906542B2 (en) * | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
| ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
| PL1698630T3 (pl) | 2005-03-03 | 2014-12-31 | Alfasigma Spa | Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| US20100285164A1 (en) * | 2009-05-11 | 2010-11-11 | Jrs Pharma | Orally Disintegrating Excipient |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| WO2014091432A1 (en) * | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
| US9018225B1 (en) * | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
-
2017
- 2017-03-22 PL PL17712504.4T patent/PL3373914T5/pl unknown
- 2017-03-22 CA CA3003108A patent/CA3003108C/en not_active Expired - Fee Related
- 2017-03-22 WO PCT/EP2017/056798 patent/WO2017162726A1/en not_active Ceased
- 2017-03-22 TR TR2019/09029T patent/TR201909029T4/tr unknown
- 2017-03-22 US US16/066,886 patent/US10842782B2/en active Active
- 2017-03-22 ES ES17712504T patent/ES2738024T5/es active Active
- 2017-03-22 HU HUE17712504 patent/HUE044432T2/hu unknown
- 2017-03-22 AU AU2017237469A patent/AU2017237469B2/en active Active
- 2017-03-22 EP EP19170192.9A patent/EP3536311B1/en active Active
- 2017-03-22 EP EP17712504.4A patent/EP3373914B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3003108C (en) | 2018-08-14 |
| US10842782B2 (en) | 2020-11-24 |
| WO2017162726A1 (en) | 2017-09-28 |
| EP3373914B2 (en) | 2022-06-01 |
| TR201909029T4 (tr) | 2019-07-22 |
| US20190008838A1 (en) | 2019-01-10 |
| CA3003108A1 (en) | 2017-09-28 |
| EP3536311A1 (en) | 2019-09-11 |
| ES2738024T5 (es) | 2022-10-24 |
| EP3373914A1 (en) | 2018-09-19 |
| AU2017237469A1 (en) | 2018-06-07 |
| EP3373914B1 (en) | 2019-04-24 |
| HUE044432T2 (hu) | 2019-10-28 |
| EP3536311B1 (en) | 2021-12-22 |
| AU2017237469B2 (en) | 2018-06-28 |
| PL3373914T5 (pl) | 2022-10-17 |
| ES2738024T3 (es) | 2020-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201413166D0 (en) | Storage kit | |
| PL3445324T3 (pl) | Kompozycja dezodorantu | |
| GB201600075D0 (en) | Immunogenci composition | |
| PL3373914T5 (pl) | Trwała przy przechowywaniu kompozycja zawierająca rifaksyminę alfa | |
| AU201617038S (en) | Storage case | |
| GB201612658D0 (en) | Composition | |
| AU201713377S (en) | Storage can | |
| GB201617908D0 (en) | Composition | |
| GB201611782D0 (en) | Composition | |
| PL3727358T3 (pl) | Mieszaniny stabilne podczas przechowywania | |
| ZA201901222B (en) | Composition comprising duddingtonia flagrans | |
| HUE055278T2 (hu) | Kriogén készítmény | |
| GB201616654D0 (en) | Composition | |
| GB201612359D0 (en) | Composition | |
| PL3727357T3 (pl) | Mieszaniny stabilne podczas przechowywania | |
| GB201615908D0 (en) | Pharmaceautical composition | |
| GB201607924D0 (en) | Composition | |
| AU201713568S (en) | storage case | |
| GB2556875B (en) | Storage assembly | |
| GB201619630D0 (en) | Composition | |
| GB201511010D0 (en) | Storage case | |
| GB201618062D0 (en) | Composition | |
| GB201616785D0 (en) | Composition | |
| GB201616772D0 (en) | Composition | |
| GB201615463D0 (en) | Composition |